zepbound is tirzepatide Eli Lilly Gets FDA Approval for for Certain Sleep Apnea Patients Eli Lilly to sell Zepbound

P., Land, L

Management strategies for gastrointestinal effects focus on dietary modifications and gradual dose escalation

It may be a fit for patients who: Have appetite regulation challenges Have signs of insulin resistance Have struggled with repeated weight loss attempts Need stronger metabolic support Have not responded as expected to other approaches Have a medical history that supports tirzepatide use Can tolerate the medication appropriately Tirzepatide may be appealing because of its dual-hormone mechanism, but stronger does not always mean better for every person

Applying it to tirzepatide would face additional challenges due to the larger molecular size